

Inclusion of sex chromosomes in noninvasive prenatal testing in Asia, Australia, Europe and the USA: A survey study

Ellen Hollands Steffensen^{1,2,3}  | Anne Skakkebæk^{2,3,4} | Kasper Gadsbøll^{5,6} |
Olav Bjørn Petersen^{5,6} | Thomas Westover⁷ | Heather Strange⁸ |
The NIPT-SCA-map Study Group | Ida Vogel^{1,3,9}

¹Center for Fetal Diagnostics, Aarhus University, Aarhus, Denmark

²Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark

³Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

⁴Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

⁵Department of Obstetrics, Center for Fetal Medicine, Pregnancy and Ultrasound, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

⁶Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

⁷Maternal-Fetal Medicine and Perinatal Genetics, Capital Health, Cooper Medical School, Rowan University, Camden, New Jersey, USA

⁸Centre for Trials Research, Cardiff University, Cardiff, UK

⁹Department of Gynaecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark

Correspondence

Ellen Hollands Steffensen, Department of Clinical Genetics, Aarhus University Hospital, Brendstrupgårdsvej 21C, DK-8200 Aarhus N, Denmark.

Email: ehs@clin.au.dk

Funding information

Aarhus University, Faculty of Health; Helsefonden, Grant/Award Number: 20-B-0065; Novo Nordisk Fonden, Grant/Award Numbers: NNF16OC0018772, NNFSA170030576; Danmarks Frie Forskningsfond, Grant/Award Number: 0134-00130B; Health Research Fund of Central Denmark Region, Grant/Award Number:

Abstract

Objective: To examine the extent to which sex chromosomes are included in current noninvasive prenatal testing (NIPT) and the reporting practices with respect to fetal chromosomal sex and sex chromosome aberrations (SCAs), in addition to an update on the general implementation of NIPT.

Method: A questionnaire addressing the research objectives was distributed by email to fetal medicine and clinical genetics experts in Asia, Australia, Europe and the USA.

Results: Guidelines on NIPT are available in the majority of the included countries. Not all existing guidelines address reporting of fetal chromosomal sex and SCAs. In most settings, NIPT frequently includes sex chromosomes (five Australian states, China, Hong Kong, Israel, Singapore, Thailand, USA and 23 of 31 European countries). This occurs most often by default or when parents wish to know fetal sex. In most settings, a potential SCA is reported by stating the risk hereof as “low” or “high” and/or by naming the SCA. Less than 50% of all pregnant women receive NIPT according to respondents from three Australian states, China, Israel, Singapore, Thailand and 24 of 31 European countries. However, this percentage, the genomic coverage of NIPT and its application as primary or secondary screening vary by setting.

Conclusion: In most of the studied countries/states, NIPT commonly includes sex chromosomes. The reporting practices concerning fetal chromosomal sex and SCAs are diverse and most commonly not addressed by guidelines. In general, NIPT is variably implemented across countries/states.

Key points

What is already known about this topic?

- Noninvasive prenatal testing (NIPT) has been widely adopted in many countries.
- NIPT allows screening for sex chromosomes including sex chromosome aberrations (SCAs); however, positive predictive values are lower than for trisomies 13, 18 and 21.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.

A2602; Health and Care Research Wales,
Grant/Award Number: HRG-18 1507

What does this study add?

- In 30 out of 38 countries surveyed, NIPT commonly includes sex chromosomes, either automatically or based on a parental wish to know fetal sex.
- Reporting practices concerning fetal chromosomal sex and SCAs based on NIPT are diverse and often not founded in guidelines.
- In most countries studied, less than 50% of pregnant women receive NIPT; however, this proportion varies substantially between settings.

1 | INTRODUCTION

Noninvasive prenatal testing (NIPT) is rapidly evolving as a prenatal genetic screening strategy. Initially established as a highly sensitive screening tool for trisomies 13, 18 and 21, NIPT has been developed to include a much broader range of genetic conditions. NIPT also allows analysis of the sex chromosomes¹ and thereby information on fetal chromosomal sex and sex chromosome aberrations (SCAs).² However, the positive predictive values of screening for SCAs using NIPT are lower than for the common trisomies. A recent study found a positive predictive value of 29.0% (95% confidence interval [CI] 18.2–42.9) for NIPT showing monosomy X and 57.5% (95% CI 40.9–73.0) for NIPT showing 47, XXY.³ Yet, interpreting these positive predictive values is not straight forward because they vary by the sample used for confirmation (chorionic villus sampling, amniocentesis, or blood from newborn)³ and depend on the population frequency which for SCAs may be unknown. In addition, the variable and potentially mild phenotype of SCAs has been raised as an important issue in discussions about the clinical utility of screening for SCAs using NIPT.^{1,4–6} Nevertheless, screening by NIPT leading to early diagnosis may enable greater parental preparedness and promote timely interventions to improve outcomes. For example, an early diagnosis of Turner syndrome allows timely screening for cardiovascular disease and early start of growth hormone therapy in line with recommendations.^{7,8} In a recent survey, parents of children with SCAs expressed a positive view on using NIPT for these conditions.⁹

In addition to detecting SCAs, including sex chromosomes in NIPT may provide information on fetal chromosomal sex with high accuracy in early gestation. A systematic review reported the sensitivity and specificity of NIPT for fetal chromosomal sex in singleton pregnancies to be 0.989 (95% CI 0.980–0.994) and 0.996 (95% CI 0.989–0.998), respectively.¹⁰ In recent studies, pregnant women and partners have expressed an interest in applying NIPT to determine the sex of the fetus^{11,12}; yet, such knowledge may have potential ethical implications.¹¹

Taken together, these perspectives on prenatal screening for fetal SCA and fetal chromosomal sex using NIPT reflect challenges faced in clinical practice. The perspectives and clinical challenges further points to the relevance of investigating the real-world implementation of this new technology.

We have previously investigated the use of NIPT in Australia, Europe and the USA.¹³ Although we reported variability within and between countries in NIPT implementation, two general strategies

were identified in countries having NIPT as a national, prenatal offer: (1) using NIPT for all pregnant women as a primary screening tool or, more commonly, (2) using NIPT for those pregnant women who were identified as at-risk on first-trimester combined screening or by age. We also reported that as of 2019, the extent to which NIPT included testing for SCAs was variable between countries and, in Australia and the USA, between states. For example, out of 30 European countries, NIPT included fetal SCA screening in addition to the common trisomies in 13 countries (in four of these as an option). In contrast, in seven countries, NIPT included the common trisomies only.

However, as NIPT continues to evolve, this picture may change. In the course of implementing prenatal screening and diagnostic technologies, experiences and practices from other settings may be of value for the international community of clinicians and researchers. This is particularly the case when those technologies pose clinical challenges such as NIPT screening for fetal SCA and fetal chromosomal sex. Therefore, the aim of this international survey study was to describe (1) the inclusion of sex chromosomes in the current typical use of NIPT as well as the reporting practices concerning fetal chromosomal sex and SCAs and (2) the general use of NIPT in Australia, the USA, and countries in Europe and Asia.

2 | METHODS

We developed a questionnaire addressing the inclusion of sex chromosomes in the typical use of NIPT and the reporting practices with respect to fetal chromosomal sex and SCAs. We aimed to distinguish between the analysis performed (that is, if testing included sex chromosomes) and what would or would not be reported (i.e., potential SCAs and/or fetal chromosomal sex) based on such an analysis. Therefore, to address the analysis performed, questions used the phrases “NIPT most commonly covers/includes [...] sex chromosomes” and “NIPT includes testing for sex chromosomes”, while we used the phrase “If NIPT is indicative of sex chromosomal aberrations (SCA) how is this reported?” to address reporting. The questionnaire was an add-on to our previous study¹³ and, as such, also contained questions regarding the general use of NIPT (complete questionnaire in Supporting Information S1). All questions were presented as multiple choice with the option of adding open-end comments.

The present study sought to update our prior findings¹³ and relied on our scientific network. In addition, we intended to include selected countries in Asia based on population size and perceived

international interest in their use of NIPT. Hence, the questionnaire was distributed by email to experts in fetal medicine and/or clinical genetics from the *NIPT-map Study Group* of our previous publication¹³ and their professional networks, as well as members of the International Faculty List of the International Society of Ultrasound in Obstetrics and Gynecology. Experts in Australia, China, Hong Kong, India, Israel, Japan, Singapore, Thailand, the USA and 42 European countries were invited during May–July 2022 to complete the questionnaire. One expert was invited to answer the survey for each of these 51 countries except for Australia, where one expert was invited for each state. In line with our prior work,¹³ we sought to obtain data from individual states in Australia and the USA where the organization of health care provision may vary between states. Responders were contacted by follow-up email for clarification of specific questions when needed. When no national data existed (such as the number of pregnant women receiving NIPT), an educated guess by contributors was accepted.

Data were compiled in a spreadsheet, and MapChart (<https://www.mapchart.net/>) was used for graphical presentation of results. No results from Asia are presented graphically due to the limited number of countries included from this continent. As such, only selected findings are presented in figures, while all results are provided in tables and Supporting Information S1.

Survey studies do not require ethical approval according to Danish law; thus, this was not obtained.

3 | RESULTS

We received survey responses from 38 out of 51 countries (China, Hong Kong, Israel, Singapore, Thailand, the USA (covering all states), 31 European countries and Australia). From Australia, responses are from Queensland, South Australia, Tasmania, Victoria and Western Australia.

3.1 | NIPT including sex chromosomes

Current practices with respect to inclusion of sex chromosomes in NIPT may be shaped by national guidelines. Of the 38 countries surveyed, 22 have national guidelines on NIPT. However, not all guidelines address the reporting of fetal sex and SCAs and when they do, recommendations vary (Table 1). For example, guidelines approve reporting fetal chromosomal sex but disapprove reporting of SCAs in Belgium and Italy. In Denmark, Estonia and the USA, reporting of both results is approved. In contrast, reporting of fetal chromosomal sex is not approved by guidelines in China. In Australia, guidelines address the poorer accuracy of NIPT analysis for sex chromosomes as compared to autosomes but they do not explicitly discuss reporting of fetal chromosomal sex or SCAs.¹⁴ However, the Australian guideline recommends that women are counseled and able to opt out of receiving this information. In England, Scotland and Wales, guidelines do not address reporting of fetal chromosomal sex or SCAs

TABLE 1 Existing guidelines on the use of noninvasive prenatal testing (NIPT) and their recommendations regarding the reporting of fetal chromosomal sex and/or sex chromosome aberrations (SCA) based on NIPT.

| No national guidelines exist ^a | National guidelines exist | | |
|---|--|--|------------------------------|
| Albania | Guidelines approve reporting of fetal chromosomal sex | Belgium | |
| Belarus | | Denmark ^b | |
| Croatia | | Estonia | |
| Cyprus | | Germany ^b | |
| Finland ^c | | Italy | |
| Greece | | Thailand | |
| Hong Kong | | USA | |
| Iceland | | Guidelines disapprove reporting of fetal chromosomal sex | China |
| Latvia | | | |
| Montenegro | | | |
| Norway | | | |
| Portugal | Guidelines approve reporting of SCA | Denmark | |
| Russia | | Estonia | |
| Serbia | | Hungary | |
| Singapore | Guidelines disapprove/recommend against reporting of SCA | USA | |
| Slovakia | | Austria | |
| | | Belgium | |
| | | France | |
| | | Italy | |
| | | Guidelines do not address reporting of both fetal chromosomal sex and of SCA | Czech Republic |
| | | | England |
| | | | Israel |
| | | | Lithuania |
| | | | The Netherlands ^d |
| | | Queensland | |
| | | Scotland | |
| | | South Australia | |
| | | Spain | |
| | | Sweden | |
| | | Switzerland | |
| | | Tasmania | |
| | | Victoria | |
| | | Wales | |
| | | Western Australia | |

^aGuidelines are currently (Spring 2022) under development in Norway, Portugal and Iceland.

^bReporting of fetal chromosomal sex is only allowed/recommended after 14 + 0 weeks of gestation (Germany) or 11 + 6 weeks of gestation (Denmark).

^cNo actual guidelines exist; however, recommendations are in place.

^dTesting for fetal chromosomal sex and SCAs is not allowed by law. Hence, this is not a subject of the guidelines.

in accordance with current practices of not including sex chromosomes in NIPT. In The Netherlands, testing for fetal chromosomal sex or SCAs is prohibited and, consequently, the Dutch guidelines do not address reporting hereof.

NIPT commonly includes testing of sex chromosomes in 30 out of 38 countries surveyed (Figures 1 and 2 and Table 2). In contrast, NIPT most commonly does *not* include sex chromosomes but *only* chromosomes 13, 18 and 21 in a minority of European countries (Austria, England, France, Norway, Scotland, Slovakia and Wales) (Figure 1 and Table 2). As shown in Figures 1 and 2 and Table 3, the proportion of all pregnant women receiving NIPT that includes sex chromosomes varies between settings from <10% (e.g., in France and Norway where NIPT only very rarely includes sex chromosomes or the Netherlands where no women have NIPT for sex chromosomes based on current legislation) to >75% in Belgium and Hong Kong. In most settings, the proportion of all the pregnant women having NIPT that includes sex chromosomes matches the proportion of all

pregnant women having NIPT regardless of the coverage confirming that NIPT as it is applied today most frequently includes testing for sex chromosomes (Figures 1 and 2, Tables 2 and 3). In the USA, an estimated >75% of all NIPT performed includes sex chromosomes. The proportions of all pregnant women receiving NIPT that includes sex chromosomes are based on an educated guess in Austria, Czech Republic, England, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Queensland, Russia, Scotland, Serbia, Singapore, Slovakia, Spain, Switzerland, Tasmania, Victoria and Western Australia.

When sex chromosomes are included in NIPT, this is done automatically (i.e., by default) in a number of countries (Table 4). However, the pregnant woman and partner may opt out of being informed about fetal chromosomal sex (this is the case in Finland, Estonia, Hong Kong, Latvia and Serbia). Conversely, parents in other settings, including Australia, Thailand and Singapore, may opt for sex chromosomes to be included in NIPT based on a wish to know fetal sex. Some responders (e.g., Finland, Italy, Sweden, Tasmania and





FIGURE 1 Inclusion of sex chromosomes in common uses of noninvasive prenatal testing (NIPT) and proportions of all pregnant women having NIPT that includes sex chromosomes in European countries. To enhance the graphical presentation, reporting categories have been collapsed as compared to Table 3. In Austria, inclusion of sex chromosomes is available on demand. Reported proportions are based on an educated guess: Austria, Czech Republic, England, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Russia, Scotland, Serbia, Singapore, Slovakia, Spain and Switzerland.

FIGURE 2 Inclusion of sex chromosomes in common uses of noninvasive prenatal testing (NIPT) and proportions of all pregnant women having NIPT that includes sex chromosomes in Australian states. To enhance the graphical presentation, reporting categories have been collapsed as compared to Table 3. Reported proportions are based on an educated guess: Queensland, Victoria and Western Australia.



Victoria) noted that the practice of including sex chromosomes in NIPT depends on the provider (e.g., variation between different companies or between public and private providers). In the USA, testing for fetal chromosomal sex and/or SCAs is decided based on shared decision-making between pregnant women/partners and clinicians.

If NIPT indicates SCA, various reporting practices are used (Table 5). In a majority of the included countries/states, results would be reported by naming the potential SCA and/or stating the probability for the potential SCA as “low” or “high” (e.g., “high probability of Turner syndrome”). A number of respondents noted that reporting practices vary by provider (e.g., Lithuania, Italy, Slovakia, the USA and Victoria).

3.2 | General use of NIPT

In most of the studied settings, NIPT is applied as a secondary test in case of increased risk during first-line screening such as first-trimester combined screening (Table S1). In contrast, NIPT is used mainly as primary screening in Albania, Belgium, Italy, Montenegro, the Netherlands and Thailand (regardless of history or risk factors) and in Germany, Norway and Victoria (in case of a pregnancy with increased a priori risk [such as age >35 years]). In some countries/states, NIPT is used both as primary *and* secondary screening. For example, this choice is at the discretion of the pregnant woman in Hungary, while it depends on the region/hospital in China, Singapore and Spain. In Queensland, Tasmania and Western Australia, use of NIPT as primary or secondary screening varies by socioeconomic

position/affordability. In the USA, patient and provider preference and insurance coverage determine the application as primary or secondary screening.

In most of the studied countries, the proportion of all pregnant women receiving NIPT (regardless of its coverage) is <50% (Table 3 and Figure S1). These proportions are based on an educated guess in Austria, England, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Queensland, Russia, Scotland, Serbia, Singapore, Slovakia, Spain, Switzerland, Tasmania, Victoria and Western Australia. However, the proportion of all pregnant women having NIPT varies across Europe and Asia from <10% to >75%. In Australia, the proportion of all pregnant women receiving NIPT ranges from 30% to 35% in Western Australia to about 50% in Victoria. Respondents from Australia, Thailand and the USA noted that adoption of NIPT varies between socioeconomic groups and/or depends on affordability.

The chromosomal/genomic coverage of NIPT is limited to chromosomes 13, 18, and 21 in a minority of the studied settings, while in a majority of settings, this coverage is extended by the inclusion of sex chromosomes and further, in some countries, a few micro-deletions (Table 1). NIPT having genomic coverage is commonly used in eight settings (Belgium, Hungary, South Australia, Switzerland, Tasmania, the USA, Victoria and Western Australia). Two or more NIPT options having differing chromosomal/genomic coverage are available and commonly used in China, the Netherlands, Portugal, Sweden, Switzerland, Victoria, the USA and Western Australia (Table 1).

The costs of NIPT are most often either self-paid or reimbursed by the healthcare system in the included countries/states (Figures 3 and 4 and Table S2). In many settings where NIPT is fully or partially

TABLE 2 Common chromosomal/genomic coverage of noninvasive prenatal testing (NIPT).

| Coverage | Country/state | |
|--|----------------------|-----------------------|
| Chromosomes 13, 18 and 21 only | Austria ^a | Portugal |
| | China | Scotland ^b |
| | England ^b | Slovakia |
| | France | Sweden |
| | The Netherlands | Wales ^b |
| | Norway | Western Australia |
| Chromosomes 13, 18, 21 and sex chromosomes | Czech Republic | Portugal |
| | Denmark | Queensland |
| | Estonia | Spain |
| | Finland | Sweden |
| | Germany | Switzerland |
| | Iceland | Tasmania |
| | Israel | Thailand |
| | Italy ^c | USA |
| | Latvia | Victoria |
| | Montenegro | Western Australia |
| Chromosomes 13, 18, 21 and a few microdeletions | Western Australia | |
| Chromosomes 13, 18, 21, a few microdeletions and sex chromosomes | Albania | Russia |
| | Belarus | Serbia |
| | China | Singapore |
| | Croatia | Spain |
| | Cyprus | Switzerland |
| | Greece | USA |
| | Hong Kong | Western Australia |
| | Lithuania | |
| Chromosomes 13, 18, 21, genome-wide coverage, but not sex chromosomes | The Netherlands | |
| Chromosomes 13, 18, 21, genome-wide coverage and sex chromosomes | Belgium | Tasmania |
| | Hungary | USA |
| | South Australia | Victoria |
| | Switzerland | Western Australia |

Note: Please note that for some countries/states, more than one common use of NIPT is listed.

^aSex chromosomes are available upon request.

^bPrivate/self-funded NIPT may include sex chromosomes. Data on uptake are extremely limited.

^cChromosomes 13, 18, 21, genome-wide coverage **and** sex chromosomes may be a choice for pregnant women in some regions.

reimbursed by a publicly funded healthcare system or health insurance, it is also available self-paid in a private setting (Denmark, England, Finland, Hong Kong, Iceland, Italy, Norway, Portugal, Scotland, Slovakia, Spain and Wales). In these countries, NIPT is often reimbursed when performed as a second-line test, while NIPT as primary screening is self-paid (e.g., Denmark, England, Hong Kong, Iceland, Italy, Scotland, Wales and in part in Spain). In Australia, NIPT is self-paid in all of the states studied, while in the USA, coverage varies between states depending on local legislation and health insurance providers.

4 | DISCUSSION

This survey study mapped the inclusion of sex chromosomes in the current use of NIPT in European and Asian countries as well as the USA and Australia. We report that not all countries have guidelines on NIPT; when they do, these do not always address the reporting of fetal chromosomal sex and SCAs. In most of the studied countries/states, sex chromosomes are commonly included when NIPT is performed. This may be the default or may be an option when pregnant women and their partners wish to know fetal sex; the inclusion of sex chromosomes is rarely because of clinical findings indicating SCAs. The proportion of all pregnant women receiving NIPT (regardless of its genomic coverage) is less than 50% in most of the included countries. However, this proportion varies between and within nations. The adoption of NIPT in terms of chromosomal/genomic coverage and application as primary or secondary screening depends not only on the country or state of residence but in some settings also follows from the individual's health insurance and/or socioeconomic conditions in combination with the available financial coverage of NIPT.

Previous studies that investigated screening for SCAs by NIPT reported similar results. For example, in a 2016–2017 survey, 24% of responding midwives and physicians from France reported testing for SCAs, while that number in Germany, Italy and Spain ranged from 53% to 57%.¹⁵ This corresponds to our finding that testing commonly does not include sex chromosomes in France. In addition, a number of countries reported to include fetal SCA screening in NIPT in our 2019 survey and to include sex chromosomes in the present study (Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Iceland, Latvia, Lithuania and the USA), while countries which in 2019 did not screen for SCAs (Norway, Austria, Slovakia and Wales) continue not to include sex chromosomes in the majority of NIPT performed. The consistent practice of commonly screening for SCAs by NIPT in the USA has recently been underlined by American College of Medical Genetics and Genomics guidelines strongly recommending such screening.¹⁶ These consistencies across time—albeit only a few years—may indicate that cultural practices around whether NIPT includes sex chromosomes have generally persisted since the introduction of NIPT in these settings.

TABLE 3 Proportion of all pregnant women receiving noninvasive prenatal testing (NIPT) (regardless of chromosomal/genomic coverage) and proportion of all pregnant women receiving NIPT for sex chromosomes.

| | | Proportion of all pregnant women receiving NIPT | | | | |
|---|--------------------|---|---------------------|------------------------------|-----------|------|
| | | <10% | 10%–24% | 25%–49% | 50%–75% | >75% |
| Proportion of all pregnant women receiving NIPT for sex chromosomes | <10% | Czech Republic | Belarus | The Netherlands ^d | | |
| | | Denmark | France ^a | | | |
| | | England | Greece | | | |
| | | Finland | Norway ^a | | | |
| | | Iceland | | | | |
| | | Israel | | | | |
| | | Latvia | | | | |
| | | Russia | | | | |
| | | Scotland | | | | |
| | | Slovakia | | | | |
| | Sweden | | | | | |
| | Wales ^a | | | | | |
| | 10%–24% | | Cyprus | China | Tasmania | |
| | | | Estonia | | | |
| | | | Hungary | | | |
| | | | Lithuania | | | |
| | | | Portugal | | | |
| | | | Switzerland | | | |
| | | | Thailand | | | |
| | 25%–49% | | | Serbia | Italy | |
| | | | Singapore | | | |
| | | | South Australia | | | |
| | | | Spain ^b | | | |
| | | | Western Australia | | | |
| 50%–75% | | | | Albania | | |
| | | | | Croatia | | |
| | | | | Germany | | |
| | | | | Victoria ^c | | |
| >75% | | | | | Belgium | |
| | | | | | Hong Kong | |

Note: In Austria, 25%–49% of all pregnant women receive NIPT. Inclusion of sex chromosomes is available on demand. In Queensland (missing response on proportion of all pregnant women receiving NIPT), >75% of NIPT performed includes sex chromosomes. Reported proportions are based on an educated guess: Austria, Czech Republic, England, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Queensland, Russia, Scotland, Serbia, Singapore, Slovakia, Spain, Switzerland, Tasmania, Victoria and Western Australia.

^aNIPT never or only very rarely includes testing for sex chromosomes.

^bThe proportion may be lower (i.e., 10%–24%) in some regions of the country.

^cAbout 50% of all pregnant women receive NIPT.

^dThe proportion of all pregnant women receiving NIPT for sex chromosomes is 0% since this is prohibited by law.

With widespread utilization of NIPT, testing for sex chromosomes follows the possibility of increasing numbers of SCAs diagnosed prenatally. Indeed, in Victoria, Australia, a prenatal diagnosis of

SCA based on amniocentesis or chorionic villus sampling occurred in 5.8 per 10,000 births in 2005 increasing to 8.7 per 10,000 births in 2020 following the introduction of NIPT.¹⁷ In 2020, 91% of 47, XXY

TABLE 4 Indications for including sex chromosomes in noninvasive prenatal testing (NIPT).

| Testing for sex chromosomes is automatically included (i.e., by default) | | Testing for sex chromosomes can be included based on a parental wish to know fetal sex | Testing for sex chromosomes can be included based on clinical findings suspicious of sex chromosome aberrations | |
|--|--------------------------------|--|---|-----------|
| Albania | Latvia ^a | Belgium | Singapore | Germany |
| Belarus | Montenegro | Croatia | Slovakia | Lithuania |
| China | Portugal Russia | Cyprus | South Australia | USA |
| Denmark | Serbia ^a | Czech Republic | Switzerland | |
| Estonia ^a | Spain | Germany | Tasmania ^b | |
| Finland ^a | Sweden | Hungary | Thailand | |
| Greece | Tasmania ^b | Israel | USA | |
| Hong Kong ^a | Victoria ^b | Italy ^a | Victoria ^b | |
| Iceland | Western Australia ^b | Lithuania | Western Australia ^b | |
| Italy ^c | | Queensland | | |

Note: Settings where NIPT never or only very rarely includes sex chromosomes are excluded. Please note that countries/states may be listed more than once.

^aThe pregnant woman may opt out of being informed about fetal chromosomal sex.

^bDepending on provider.

^cNIPT performed by private operators mostly includes sex chromosomes by default, whereas in the public healthcare system this relies on pre-test counseling.

TABLE 5 Reporting of a noninvasive prenatal screening result indicative of a sex chromosome aberration (SCA).

| Reporting phrase | Country/state | |
|--|----------------|-------------------|
| "Normal" or "abnormal" with respect to sex chromosomes | Italy | |
| | Thailand | |
| | USA | |
| "Low probability" or "high probability" with respect to SCA | Albania | Portugal |
| | Belarus | Queensland |
| | Cyprus | Serbia |
| | Denmark | Singapore |
| | Estonia | South Australia |
| | Finland | Spain |
| | Hong Kong | Tasmania |
| | Israel | USA |
| | Italy | Western Australia |
| The amount/number of chromosomes Y and X material detected is reported | China | Lithuania |
| | Denmark | Portugal |
| | Germany | Sweden |
| The specific, potential SCA is named | Croatia | Serbia |
| | Cyprus | Singapore |
| | Czech Republic | South Australia |
| | Greece | Switzerland |
| | Hungary | Tasmania |
| | Latvia | Western Australia |
| | Russia | |

Note: Please note that countries/states may be listed more than once.

cases had been detected through NIPT.¹⁷ Similar trends are likely in those countries studied here where a high proportion of pregnant women have NIPT, sex chromosomes are commonly included in NIPT and potential SCAs are reported. However, our findings show that although sex chromosomes in some settings are commonly (and sometimes per default) included in NIPT, this does not necessarily mean that potential SCAs are reported. Examples include Belgium and Finland, where NIPT performed in the public sector usually includes assessment for fetal chromosomal sex but not for SCAs. Thus, diverse reporting practices mean that findings such as those reported from Victoria¹⁷ may not necessarily be extrapolated to other settings.

Likewise, including sex chromosomes in NIPT does not necessarily mean reporting fetal chromosomal sex. In many settings, parents may opt out of knowing fetal chromosomal sex, while in other settings reporting fetal sex is prohibited (China) or restricted until a certain gestational age is reached in accordance with guidelines (Denmark) or the law (Germany).¹⁸ This exemplifies how the ethical considerations about testing for fetal chromosomal sex using NIPT are translated into real world practices. Concerns have been raised that introducing NIPT could facilitate sex selective termination of pregnancy.^{11,12} A skewed sex ratio at birth toward more males has previously been reported (e.g., in China) as a result of increased availability of prenatal ultrasound in the 1980s¹⁹ with a continued rise after 2000.²⁰ However, a recent study found that the male-female ratio at birth declined in China from 2010 to 2020.²¹ Nevertheless, more research is needed to investigate the potential impact of NIPT utilization on sex-selection. Such investigations rely on high quality census data available for researchers to follow trends in sex ratio at birth—particularly in countries where fetal chromosomal sex determination by NIPT is accessible.

The proportion of all pregnant women receiving NIPT appears to be stable in most European countries compared with results from our




FIGURE 3 Financial coverage of noninvasive prenatal testing (NIPT) in European countries. For Australia, China, Hong Kong, Singapore and Thailand: see text and Table S2.

2019 survey.¹³ Exceptions are Croatia and Germany where proportions increased from <25% to 50%–75% in both countries. However, care should be taken when interpreting these findings, since the estimation of the percentage of women receiving NIPT is uncertain in many settings and because of answers provided as intervals. Further, the present study confirms our prior finding that when NIPT is performed within a public health care setting, this is often as a second tier test for pregnant women at high risk after first-trimester combined screening for the common trisomies or based on age¹³ (China, Denmark, England, Finland, France, Hong Kong, Iceland, parts of Italy, Norway, Scotland, South Australia, parts of Singapore, parts of Spain, Sweden, Tasmania and Wales). In many of these countries/states, NIPT is additionally available in a private setting for pregnant women paying out-of-pocket and here, more often used as primary screening. However, information on this use of NIPT and on the percentage of women accessing NIPT privately is limited. In contrast to this trend, more state Medicaid programs in the USA now cover NIPT as primary screening compared with 2019¹³ (21 vs. six).

Despite the tendencies described above, we found variability in the utilization and availability of NIPT across countries as previously reported.^{13,15,22} This heterogeneity exists both within (e.g., Australia,

Italy, Spain, Sweden and the USA) and between countries when it comes to chromosomal/genomic coverage of NIPT, proportions of pregnant women receiving NIPT, application of NIPT as primary or secondary screening, reporting practices and financial coverage of testing. One contributor to this heterogeneity is provider variability when different private companies operate in a country and/or both private and public offers co-exist. As reported previously,^{23–25} socioeconomic status is another contributor to prenatal screening and testing heterogeneity. This may especially be true when the adoption of NIPT depends on non-universal health insurance and/or payment out-of-pocket, as commented by some respondents in the present survey. As noted in a recent review, potential inequity of access adds to the list of ethical issues surrounding NIPT for SCAs.⁶ However, not only external factors influence the use of NIPT, since this is also a matter of personal attitude.²⁶

4.1 | Strengths and limitations

This study is limited by national data not being routinely collected or available in all settings, leaving some of the replies based on an




FIGURE 4 Financial coverage of noninvasive prenatal testing (NIPT) by state Medicaid programs in the USA. In three states (LA, TX and LA) coverage for all pregnant women is currently under consideration.

educated guess (for example, the proportion of pregnant women receiving NIPT). This may particularly be the case for countries where NIPT is mostly available in a private setting.

Further, replies to the survey were obtained mainly through our scientific network, thereby limiting the geographical scope of the study. Nevertheless, we acknowledge the importance of studying the current use of NIPT not only in the countries/states included in this work, and we encourage such research worldwide.

Finally, given the study's simple design and its aim of obtaining information on the most common adoptions of NIPT, details and nuances of the current practice could not be completely covered in this publication.

5 | CONCLUSION

We found that across countries in Asia and Europe and states in Australia and the USA, NIPT commonly includes testing for sex chromosomes and this is often done either by default or based on a parental wish to know fetal sex. Yet, only a subset of countries has national guidelines on the reporting of SCAs and fetal chromosomal sex and the reporting practices in case NIPT is suggestive of SCA are variable. In most of the studied settings, an estimated <50% of pregnant women have NIPT; however, utilization of NIPT varies. This variation may be related to, for example, the availability of a national/regional prenatal screening offer and the pregnant woman's/couple's ability to pay for private testing.

THE NIPT-SCA-MAP STUDY GROUP

Amihod Singer, Genetic Department, Israel Ministry of Health, Jerusalem, Israel. Anila Babameto-Laku, Service of Medical Genetics, University Hospital Center "Mother Theresa", Faculty of Medicine, Tirana, Albania. Anita Rauch, University of Zurich, Institute of Medical Genetics, Schlieren, Switzerland. Anna Kulpanovich, National Medical Center "Mother and Child", Genetic Unit, Minsk, Belarus. Bo Jacobsson, Department of Obstetrics and Gynecology, University of Gothenburg and Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden. Boonsri Chanrachakul, Samitivej Sukumvit Hospital, Bangkok, Thailand. Egle Machtejeviene, Department of Obstetrics and Gynecology, Lithuanian University of Health Sciences, Kaunas, Lithuania. Fanwei Zeng, University of Copenhagen, Denmark, and BGI Genomics Co., Ltd., China. Feodora Stipoljev, Department of Laboratory Cytogenetics, Clinic of Obstetrics and Gynecology, Clinical Hospital "Sveti Duh", Zagreb, Faculty of Medicine, University of Osijek, Osijek, Croatia. Ferenc Szirko, East-Tallinn Central Hospital, Tallinn, Estonia. Francesca Romana Grati, Research and Development, Cytogenetics and Medical Genetics Unit, TOMA Advanced Biomedical Assays, S.p.A. (Impact Lab), Busto Arsizio, Varese, Italy. Greg Duncombe, University of Queensland, Brisbane, Australia. Hanns Helmer, Department of Obstetrics & Gynecology, Medical University of Vienna, Austria. Hulda Hjartardóttir, Landspítali University Hospital, Reykjavík, Iceland. Igor N. Lebedev, Research Institute of Medical Genetics, Tomsk National Research

Medical Center of the Russian Academy of Sciences, Tomsk, Russia. Ivana Joksic, Gynecology and Obstetrics Clinic "Narodni front", Genetics Laboratory Department, Belgrade, Serbia. Jan E. Dickinson, The University of Western Australia, Perth, Australia. Joana B. Melo, Cytogenetics and Genomics Lab, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. Joris Robert Vermeesch, Department of Human Genetics, KU Leuven, Leuven, Belgium. Kjell Å. Salvesen, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Department of Obstetrics and Gynecology, Trondheim University Hospital, Trondheim, Norway. Lindsay Edwards, Royal Hobart Hospital, Hobart, Australia. Lisa Hui, University of Melbourne and Murdoch Children's Research Institute, Melbourne, Australia. Malgorzata I. Srebniak, Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands. Marta Rodriguez de Alba, Genetics Department, Fundación Jiménez Díaz, Madrid, Spain. Natalija Vedmedovska, Riga Stradiņš University, Riga Maternity Hospital, IVF Riga Holding - Genetic Unit, Riga, Latvia. Olga Török, University of Debrecen, Department of Obstetrics and Gynecology, Debrecen, Hungary. Olivera Miljanovic Clinical Center of Montenegro - Center for Medical Genetics and Immunology, Podgorica, Montenegro. Pavel Calda, Department of Obstetrics and Gynecology, First Medical Faculty, Charles University, Prague, Czech Republic. Peter Celec, Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovakia. Peter Muller, Women's and Children's Hospital, North Adelaide, Australia. Philippos Patsalis, NIPD Genetics Public Company Limited, Nicosia, Cyprus. Kwong Wai Choy, Department of Obstetrics & Gynecology, Chinese University of Hong Kong, Hong Kong, China. Tai Wai Yeo, KK Women's and Children's Hospital, Singapore. Thomas Liehr, Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany. Vedran Stefanovic, Department of Obstetrics and Gynecology, Fetomaternal Medical Center, Helsinki University Hospital and University of Helsinki, Finland. Vincent Gatinois, Unité de Génétique Chromosomique, CHU de Montpellier, France. Voula Velissariou, Genetics and Molecular Biology, Bioiatriki Healthcare Group, Athens, Greece.

ACKNOWLEDGMENTS

We appreciate the contributions made by the NIPT-SCA-map study group for this research. Ellen Hollands Steffensen is funded by the faculty of Health at Aarhus University, the Health Research Fund of Central Denmark Region (A2602), and Helsefonden (20-B-0065). Anne Skakkebak is funded by the Independent Research Fund Denmark (0134-00130B). Olav Bjørn Petersen holds a professorship funded by the Novo Nordisk Foundation (grant NNFS170030576). Heather Strange is funded by Health and Care Research Wales (HRG-18 1507). Ida Vogel is funded by the Novo Nordisk Foundation (NNF16OC0018772).

CONFLICT OF INTEREST STATEMENT

The authors report no conflicts of interest in relation to this article.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon request.

ORCID

Ellen Hollands Steffensen  <https://orcid.org/0000-0003-0216-9646>

REFERENCES

- Christiaens L, Chitty LS, Langlois S. Current controversies in prenatal diagnosis: expanded NIPT that includes conditions other than trisomies 13, 18, and 21 should be offered. *Prenat Diagn*. 2021; 41(10):1316-1323. <https://doi.org/10.1002/pd.5943>
- Mazloom AR, Džakula Ž, Oeth P, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. *Prenat Diagn*. 2013;33(6): 591-597. <https://doi.org/10.1002/pd.4127>
- Lüthgens K, Grati FR, Sinzel M, Habig K, Kagan KO. Confirmation rate of cell free DNA screening for sex chromosomal abnormalities according to the method of confirmatory testing. *Prenat Diagn*. 2021;41(10):1258-1263. <https://doi.org/10.1002/pd.5814>
- Shaw J, Scotchman E, Chandler N, Chitty LS. PREIMPLANTATION GENETIC TESTING: non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disorders. *Reproduction*. 2020;160(5):A1-A11. <https://doi.org/10.1530/rep-19-0591>
- Reiss RE, Discenza M, Foster J, Dobson L, Wilkins-Haug L. Sex chromosome aneuploidy detection by noninvasive prenatal testing: helpful or hazardous? *Prenat Diagn*. 2017;37(5):515-520. <https://doi.org/10.1002/pd.5039>
- Johnston M, Warton C, Pertile MD, et al. Ethical issues associated with prenatal screening using non-invasive prenatal testing for sex chromosome aneuploidy. *Prenat Diagn*. 2022;1-9.
- Pieters JJPM, Verhaak CM, Braat DDM, van Leeuwen E, Smits APT. Experts' opinions on the benefit of an incidental prenatal diagnosis of sex chromosomal aneuploidy: a qualitative interview survey. *Prenat Diagn*. 2012;32(12):1151-1157. <https://doi.org/10.1002/pd.3975>
- Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. *Eur J Endocrinol*. 2017;177(3):G1-G70. <https://doi.org/10.1530/eje-17-0430>
- Samango-Sproule CA, Porter GF, Lasutschinkow PC, Tran SL, Sadeghin T, Gropman AL. Impact of early diagnosis and noninvasive prenatal testing (NIPT): knowledge, attitudes, and experiences of parents of children with sex chromosome aneuploidies (SCAs). *Prenat Diagn*. 2020;40(4):470-480. <https://doi.org/10.1002/pd.5580>
- Mackie FL, Hemming K, Allen S, Morris R, Kilby M. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. *BJOG*. 2017;124(1):32-46. <https://doi.org/10.1111/1471-0528.14050>
- Bowman-Smart H, Savulescu J, Gyngell C, Mand C, Delatycki MB. Sex selection and non-invasive prenatal testing: a review of current practices, evidence, and ethical issues. *Prenat Diagn*. 2020;40(4): 398-407. <https://doi.org/10.1002/pd.5555>
- Haidar H, Le Clerc-Blain J, Vanstone M, et al. A qualitative study of women and partners from Lebanon and Quebec regarding an expanded scope of noninvasive prenatal testing. *BMC Pregnancy Childbirth*. 2021;21(1):54. <https://doi.org/10.1186/s12884-020-03538-y>
- Gadsbøll K, Petersen OB, Gatinois V, et al. Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation. *Acta Obstet Gynecol Scand*. 2020;99(6):722-730. <https://doi.org/10.1111/aogs.13841>

14. Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Human Genetics Society Australasia. Prenatal screening and diagnosis of chromosomal and genetic conditions in the fetus in pregnancy. 2018. Accessed September 20, 2022. <https://ranzocg.edu.au/wp-content/uploads/2022/05/Prenatal-Screening-and-Diagnostic-Testing-for-Fetal-Chromosomal-and-Genetic-Conditions.pdf>
15. Benachi A, Caffrey J, Calda P, et al. Understanding attitudes and behaviors towards cell-free DNA-based noninvasive prenatal testing (NIPT): a survey of European health-care providers. *Eur J Med Genet.* 2020;63(1):103616. <https://doi.org/10.1016/j.ejmg.2019.01.006>
16. Dungan JS, Klugman S, Darilek S, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2022.
17. Loughry L, Pynaker C, White M, et al. State-wide increase in prenatal diagnosis of klinefelter syndrome on amniocentesis and chorionic villus sampling: impact of non-invasive prenatal testing for sex chromosome conditions. *Prenat Diagn.* 2022;1-9.
18. Kozłowski P, Burkhardt T, Gembruch U, et al. DEGUM, ÖGUM, SGUM and FMF Germany recommendations for the implementation of first-trimester screening, detailed ultrasound, cell-free DNA screening and diagnostic procedures. *Ultraschall Med.* 2019;40(2):176-193. <https://doi.org/10.1055/a-0631-8898>
19. Chen Y, Li H, Meng L. Prenatal sex selection and missing girls in China: evidence from the diffusion of diagnostic ultrasound. *J Hum Resour.* 2013;48(1):36-70. <https://doi.org/10.1353/jhr.2013.0003>
20. Jiang Q, Yu Q, Yang S, Sánchez-Barricarte JJ. Changes in sex ratio at birth in China: a decomposition by birth order. *J Biosoc Sci.* 2017;49(6):826-841. <https://doi.org/10.1017/s002193201600547>
21. Jiang Q, Zhang C. Recent sex ratio at birth in China. *BMJ Glob Health.* 2021;6(5):e005438. <https://doi.org/10.1136/bmjgh-2021-005438>
22. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. *Prenat Diagn.* 2015;35(10):959-967. <https://doi.org/10.1002/pd.4637>
23. Ellison J, Wang C, Yarrington C, Connors P, Hanchate A. Insurance and geographic variations in non-invasive prenatal testing. *Prenat Diagn.* 2022;42(8):1004-1007. <https://doi.org/10.1002/pd.6155>
24. Hui L, Barclay J, Poulton A, Hutchinson B, Halliday JL. Prenatal diagnosis and socioeconomic status in the non-invasive prenatal testing era: a population-based study. *Aust N Z J Obstet Gynaecol.* 2018;58(4):404-410. <https://doi.org/10.1111/ajo.12778>
25. van der Meij KRM, Kooij C, Bekker MN, Galjaard RH, Henneman L. Non-invasive prenatal test uptake in socioeconomically disadvantaged neighborhoods. *Prenat Diagn.* 2021;41(11):1395-1400. <https://doi.org/10.1002/pd.6043>
26. Kuppermann M, Learman LA, Gates E, et al. Beyond race or ethnicity and socioeconomic status: predictors of prenatal testing for Down syndrome. *Obstet Gynecol.* 2006;107(5):1087-1097. <https://doi.org/10.1097/01.aog.0000214953.90248.db>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Steffensen EH, Skakkebaek A, Gadsbøll K, et al. Inclusion of sex chromosomes in noninvasive prenatal testing in Asia, Australia, Europe and the USA: a survey study. *Prenat Diagn.* 2023;1-12. <https://doi.org/10.1002/pd.6322>